Results 41 to 50 of about 125,674 (260)

circCRKL, a circRNA derived from CRKL, regulates BCR-ABL via sponging miR-877-5p to promote chronic myeloid leukemia cell proliferation

Journal of Translational Medicine, 2022
Background The BCR-ABL fusion protein is the key factor that results in the occurrence of chronic myeloid leukemia (CML). Imatinib (IM) is a targeted inhibitor of BCR-ABL to achieve complete remission.
Jianming Wang, Yang Liang, Yuefeng Qin, Guoyun Jiang, Yuhang Peng, Wenli Feng   +5 more
doaj   +1 more source

Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition

Journal of the National Cancer Institute, 2017
Background Imatinib and second-generation tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib have statistically significantly improved the life expectancy of chronic myeloid leukemia (CML) patients; however, resistance to TKIs remains a major ...
Rebecca J. Mitchell, L. Hopcroft, Pablo Baquero, E. Allan, K. Hewit, Daniel James, G. Hamilton, A. Mukhopadhyay, J. O'prey, A. Hair, Junia V. Melo, Edmond Y. W. Chan, Kevin M. Ryan, V. Maguer-Satta, B. Druker, Richard E Clark, S. Mitra, P. Herzyk, F. Nicolini, P. Salomoni, Emma Shanks, B. Calabretta, T. Holyoake, G. Helgason   +23 more
semanticscholar   +1 more source

Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-Abl

Molecular Cancer, 2010
Background Chronic myelogenous leukemia (CML) is characterized by the chimeric tyrosine kinase Bcr-Abl. Bcr-Abl-T315I is the notorious point mutation that causes resistance to imatinib and the second generation tyrosine kinase inhibitors, leading to poor
Cao Qi, Li Juan, Chen Chun, Jin Yanli, Lu Zhongzheng, Pan Jingxuan   +5 more
doaj   +1 more source

Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition

Journal of Hematology & Oncology, 2020
Background The Philadelphia chromosome (Ph), which leads to the creation and expression of the fusion gene product BCR-ABL, underlines the pathogenesis of chronic myelogenous leukemia (CML) and a fraction of adult and pediatric acute B-lymphoblastic ...
Xinhua Xiao, Ping Liu, Donghe Li, Zhizhou Xia, Peihong Wang, Xiuli Zhang, Mingzhu Liu, Lujian Liao, Bo Jiao, Ruibao Ren   +9 more
doaj   +1 more source

A dual origin for Bcr-Abl gene translocation/fusion as dynamics of synergism of the hematopoietic stem cell and hemangioblast in chronic myeloid leukemia [PDF]

, 2015
Contextual BCR-ABL tyrosine kinase over-activity determines in formulated fashion the emergence of proliferation and anti-apoptosis that arise largely as derived phenomena of otherwise homeostatic mechanisms of the c-ABL gene within hematopoietic ...
Agius, Lawrence M.
core   +1 more source

Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase

Scientific Reports, 2018
Chronic myelogenous leukemia (CML) is characterized by the oncogenic fusion protein, BCR-ABL protein kinase, against which clinically useful inhibitors have been developed. An alternative approach to treat CML is to degrade the BCR-ABL protein. Recently,
N. Shibata, K. Shimokawa, Katsunori Nagai, Nobumichi Ohoka, T. Hattori, Naoki Miyamoto, O. Ujikawa, Tomoya Sameshima, H. Nara, N. Cho, M. Naito   +10 more
semanticscholar   +1 more source

Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study. [PDF]

PLoS ONE, 2013
BCR-ABL kinase domain inhibition can be used to treat chronic myeloid leukemia. The inhibitors such as imatinib, dasatinib and nilotinib are effective drugs but are resistant to some BCR-ABL mutations.
Karunakar Tanneeru, Lalitha Guruprasad
doaj   +1 more source

Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation

Haematologica, 2008
Treatment with imatinib is very effective in Bcr-Abl positive leukemia. However, development of resistance to this drug is a common phenomenon in late stage disease.
Rama Krishna Kancha, Nikolas von Bubnoff, Cornelius Miething, Christian Peschel, Katharina S. Götze, Justus Duyster   +5 more
doaj   +1 more source

Suppression of autophagy by BCR ABL

Frontiers in Bioscience, 2012
Imatinib and second generation BCR/ABL tyrosine kinase inhibitors (TKIs) serve now as standard therapies for patients with chronic myelogenous leukemia (CML); however, CML stem cells are intrinsically insensitive to the cell death-inducing effects of TKIs, allowing the persistence of a "reservoir" of BCR/ABL-expressing CML-initiating cells potentially ...
CALABRETTA, Bruno, SALOMONI, Paolo
openaire   +4 more sources

Neuropsychiatric Symptoms Mimicking Dementia in a Patient Treated With Imatinib

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Tyrosine kinase inhibitors are the cornerstone of chronic myeloid leukemia treatment. Newer agents have more potency and a broader spectrum of action, but also a higher potential for neuropsychiatric side effects. We present a case of a patient on imatinib who developed progressive cognitive, mood, and behavioral alterations.
Ashley Jones, Samuele Bonomi, Keith E. Stockerl‐Goldstein, Randall J. Bateman   +3 more
wiley   +1 more source